1
|
Shen Z, Xu Q, Jin L. Structured procedures promote placebo effects. JOURNAL OF EXPERIMENTAL SOCIAL PSYCHOLOGY 2020. [DOI: 10.1016/j.jesp.2020.104029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
2
|
Ahmid M, Ahmed SF, Shaikh MG. Childhood-onset growth hormone deficiency and the transition to adulthood: current perspective. Ther Clin Risk Manag 2018; 14:2283-2291. [PMID: 30538484 PMCID: PMC6260189 DOI: 10.2147/tcrm.s136576] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Childhood-onset growth hormone deficiency (CO-GHD) is an endocrine condition associated with a broad range of health issues from childhood through to adulthood, which requires particular attention during the transition period from adolescence to young adulthood. There is uncertainty in the clinical practice of the management of CO-GHD during transition regarding the clinical assessment and management of individual patients during and after transition to obtain optimal follow-up and improved health outcomes. Despite the availability of clinical guidelines providing the framework for transition of young adults with CO-GHD, there remains substantial variation in approaching transitional care among pediatric and adult services. A well-structured and coordinated transitional plan with clear communication and direct collaboration between pediatric and adult health care to ensure optimal management of adolescents with CO-GHD during transition is needed.
Collapse
Affiliation(s)
- M Ahmid
- Development Endocrinology Research Group, School of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow, UK,
| | - S F Ahmed
- Development Endocrinology Research Group, School of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow, UK,
| | - M G Shaikh
- Development Endocrinology Research Group, School of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow, UK,
| |
Collapse
|
3
|
Improda N, Capalbo D, Esposito A, Salerno M. Muscle and skeletal health in children and adolescents with GH deficiency. Best Pract Res Clin Endocrinol Metab 2016; 30:771-783. [PMID: 27974190 DOI: 10.1016/j.beem.2016.11.012] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
In addition to promoting linear growth, GH plays a key role in the regulation of bone and muscle development and metabolism. Although GH deficiency is frequently listed among the causes of secondary osteoporosis in children, its impact on bone and muscle health and on fracture risk is still not completely established. Current data suggest that childhood-onset GH deficiency can affect bone and muscle mass and strength, with GH replacement therapy exerting beneficial effects. Moreover, GH withdrawal at final height can result in reduced peak bone and muscle mass, potentially leading to increased fracture risk in adulthood. Thus, the muscle-bone unit in GH deficient subjects should be monitored during childhood and adolescence in order to prevent osteoporosis and increased fracture risk and GH replacement should be tailored to ensure an optimal bone and muscle health.
Collapse
Affiliation(s)
- Nicola Improda
- Department of Medical Translational Sciences, Paediatric Endocrinology Section, Federico II University, Via S. Pansini 5, 80131 Naples, Italy.
| | - Donatella Capalbo
- Department of Paediatrics, Federico II University, Via S. Pansini 5, 80131 Naples, Italy.
| | - Andrea Esposito
- Department of Medical Translational Sciences, Paediatric Endocrinology Section, Federico II University, Via S. Pansini 5, 80131 Naples, Italy.
| | - Mariacarolina Salerno
- Department of Medical Translational Sciences, Paediatric Endocrinology Section, Federico II University, Via S. Pansini 5, 80131 Naples, Italy.
| |
Collapse
|
4
|
Abstract
Human growth hormone (hGH) is a proteohormone secreted by the pituitary gland. It acts through binding to the hGH receptor, inducing either direct effects or initiating the production of insulin-like growth-factor I (IGF-I), the most important mediator of hGH effects. Growth hormone is primarily known to promote longitudinal growth in children and adolescents, but has also various important metabolic functions throughout adult life. Effects of hGH on the adult organism are well established from studies with recombinant growth hormone (rhGH) therapy in growth hormone deficient subjects. In this particular group of patients, replacement of hGH leads to increased lipolysis and lean body mass, decreased fat mass, improvements in VO(2max), and maximal power output. Although extrapolation from these findings to the situation in well trained healthy subjects is impossible, and controlled studies in healthy subjects are scarce, abuse of hGH seems to be popular among athletes trying to enhance physical performance. Detection of the application of rhGH is difficult, especially because the amino acid sequence of rhGH is identical to the major 22,000 Da isoform of hGH normally secreted by the pituitary. Furthermore, some physiological properties of hGH secretion also hindered the development of a doping test: secreted in a pulsatile manner, it has a very short half-life in circulation, which leads to highly variable serum levels. Concentration alone therefore cannot prove the exogenous administration of hGH.Two approaches have independently been developed for the detection of hGH doping: The so-called "marker approach" investigates changes in hGH-dependent parameters like IGF-I or components of bone and collagen metabolism, which are increased after hGH injection. In contrast, the so-called "isoform approach" directly analyses the spectrum of molecular isoforms in circulation: the pituitary gland secretes a spectrum of homo- and heterodimers and - multimers of a variable spectrum of hGH isoforms, whereas rhGH consists of the monomeric 22,000 Da isoform only. This isoform therefore becomes predominant after injection of rhGH. Specific immunoassays with preference for the one or the other isoform allow analysis of the relative abundance of the 22,000 Da isoform. Application of rhGH can be proven when the ratio of this isoform relative to the others is increased above a certain threshold. Because the "marker method" and the "isoform method" have a different window of opportunity for detection, complementary use of both tests could be a way to increase the likelihood of detecting cheating athletes.
Collapse
Affiliation(s)
- Martin Bidlingmaier
- Medizinische Klinik - Innenstadt, Ludwig-Maximilians University, Ziemssenstr. 1, 80336, Munich, Germany.
| | | |
Collapse
|
5
|
Sartorio A, Agosti F, De Col A, Mazzilli G, Marazzi N, Busti C, Galli R, Lafortuna CL. Muscle strength and power, maximum oxygen consumption, and body composition in middle-aged short-stature adults with childhood-onset growth hormone deficiency. Arch Med Res 2007; 39:78-83. [PMID: 18067999 DOI: 10.1016/j.arcmed.2007.06.011] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2007] [Accepted: 06/11/2007] [Indexed: 11/16/2022]
Abstract
BACKGROUND Growth hormone (GH) replacement in adult GH-deficient (GHD) patients is reported to have a long-term beneficial effect on muscle mass and function, these effects being greater in young males and in adult-onset compared with those with childhood-onset GHD. To date, more discordant data are reported on the degree of muscle impairment in untreated GHD patients, due to the large heterogeneity of this syndrome. METHODS Muscle maximum total isotonic strength (ST), lower limb maximum power output (W), maximum aerobic capacity (VO(2)max) and body composition (by tetrapolar bio-impedentiometry) were evaluated in seven short-stature adults with childhood-onset GHD and in seven age-matched normal-stature controls with comparable lifestyle and daily physical activity. RESULTS Significant differences were found in body composition between control subjects and GHD patients, who presented higher adiposity (mean BMI+/-SD: GHD, 27.8+/-5.8 kg/m(2); controls, 22.1+/-0.8 kg/m(2); p=0.047), larger fat mass (GHD, 21.8+/-10.7 kg; controls, 8.8+/-3.5 kg; p=0.008), and lower fat-free mass (GHD, 65.8+/-11.4 %; controls, 87.0+/-6.5 %; p=0.002). In absolute terms, GHD patients attained significantly lower values in ST (GHD, 2479+/-493 N; controls, 4578+/-1476 N; p=0.008), W (GHD, 1092+/-452 W; controls, 1910+/-781 W; p=0.035) and VO(2)max (GHD, 1.68+/-0.40 l/min; controls, 2.67+/-0.84 l/min; p=0.035) than those attained by controls. The differences were still evident when the results were normalized by unit body mass, whereas they disappeared when the parameters were expressed per unit fat-free mass, suggesting for these patients the presence of an intrinsic muscle function in the same range as that of control subjects. CONCLUSIONS Middle-aged and short-stature adults with childhood-onset GHD, who received discontinuous pit-GH substitution therapy only during childhood and have uncorrected long-lasting GHD, still retain a normal intrinsic muscle capability in attaining isotonic strength, generating anaerobic power as well as accomplishing oxidative processes. Nonetheless, it is not known which age-dependent evolution in motor dysfunction could be expected in this subgroup of GHD patients, when ageing processes add up to hormonal deficiencies.
Collapse
Affiliation(s)
- Alessandro Sartorio
- Division of Metabolic Diseases, Italian Institute for Auxology, IRCCS, Verbania and Milan, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
6
|
Fernandez AM, LeRoith D. Skeletal Muscle. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2005; 567:117-47. [PMID: 16370138 DOI: 10.1007/0-387-26274-1_5] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
7
|
Abstract
Human hGH is listed as a prohibited class E substance by the International Olympic Committee (IOC), and its use is considered as doping. However, until today the likelihood of being punished for using recombinant hGH is very limited: once injected, it is believed to be undetectable by laboratories. No official test is implemented in the doping control procedures, and the only situation when athletes were found guilty of doping with hGH arose from actions of customs officers or policemen arresting athletes carrying ampoules with them. The primary reason for the lack of an accepted test method is the amino acid sequence identity between the main fraction of pituitary derived hGH and recombinant hGH, which makes it difficult to discriminate between endogenous and exogenous hGH. In addition, hGH is known to have a very short half-life time in circulation of around 15 min. Recent efforts of endocrine researchers led to the identification of two main strategies promising to be useful for the detection of recombinant hGH application, which are reviewed in this article: on the one hand, changes in GH-dependent parameters after administration of recombinant GH have been shown to be possible indicators of GH abuse, because the increase in various parameters following recombinant hGH administration exceeds the variability commonly observed in normal, healthy subjects. More directly, another approach focuses on changes in the hGH isoform pattern in serum occurring after injection of recombinant hGH. Because of the negative feedback on pituitary hGH secretion, the relative abundance of isoforms other than 22 kD are greatly reduced after administration of recombinant hGH, which only consists of the 22 kD hGH isoform.
Collapse
Affiliation(s)
- M Bidlingmaier
- Neuroendocrine Unit, Medizinische Klinik- Innenstadt, Klinikum der Ludwig-Maximilians - University, Munich, Germany.
| | | | | |
Collapse
|
8
|
Werlang Coelho C, Rebello Velloso C, Resende de Lima Oliveira Brasil R, Vaisman M, Gil Soares de Araújo C. Muscle power increases after resistance training in growth-hormone-deficient adults. Med Sci Sports Exerc 2002; 34:1577-81. [PMID: 12370558 DOI: 10.1097/00005768-200210000-00008] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
PURPOSE To measure the effects of a resistance training (RT) program over muscle function and body composition of adults with GH deficiency without replacement. METHODS 11 GH-deficient patients (39 +/- 11 yr) were evaluated in four occasions (two pretraining and at 6 and 12-wk of training). We performed anthropometric measurements and physical tests. Muscle power was measured by a specific tensiometer (Fitro, Bratislava, Slovakia) in five different exercises: seated chest press, rear lat pull-down, knee extension, standing upright row, and triceps press down. Muscle endurance was assessed by maximum number of sit-ups and maximum static strength by measurement with a handgrip dynamometer. A 12-wk home-based RT program was individually prescribed and consisted of 13 exercises, performed each other day, using simple material. RESULTS No significant differences occurred in body weight or limb circumferences ( > 0.05), although the sum of central skinfolds decreased with RT (111 +/- 9 vs 100 +/- 9 mm; < 0.05). RT induced significant gains in four of five exercises: rear lat pull-down (141 +/- 19 vs 198 +/- 20 W), standing upright row (134 +/- 22 vs 157 +/- 24 W), triceps press down (85 +/- 14 vs 123 +/- 21 W), and seated chest press (114 +/- 20 vs 143 +/- 21 W; < 0.05). Sit-up results also showed significant improvements, while handgrip did not ( > 0.05). CONCLUSION GH-deficient adults without GH replacement may improve their maximum muscle power when submitted to an individualized, simple, and short home-based RT program. Considering that limb girths did not significantly change, the gains were most likely due to improvements in neuromuscular components.
Collapse
Affiliation(s)
- Carla Werlang Coelho
- Physical Education Graduate Program, Universidade Gama Filho, Rio de Janeiro, Brazil
| | | | | | | | | |
Collapse
|
9
|
Feinberg MS, Scheinowitz M, Laron Z. Echocardiographic dimensions and function in adults with primary growth hormone resistance (Laron syndrome). Am J Cardiol 2000; 85:209-13. [PMID: 10955379 DOI: 10.1016/s0002-9149(99)00642-6] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Patients with primary growth hormone (GH) resistance-Laron Syndrome (LS)-have no GH signal transmission, and thus, no generation of circulating insulin-like growth factor-I (IGF-I), and should serve as a unique model to explore the controversies concerning the longterm effect of GH/IGF-I deficiency on cardiac dimension and function. We assessed 8 patients with LS (4 men, 4 women) with a mean (+/- SD) age of 38+/-7 years (range 22 to 45), and 8 aged-matched controls (4 men, 4 women) with a mean age of 38+/-9 years (range 18 to 47) by echocardiography at rest, following exercise, and during dobutamine administration. Left ventricular (LV) septum, posterior wall, and end-diastolic diameter were significantly reduced in untreated patients with LS compared with the control group (p<0.05 for all). Systolic Doppler-derived parameters, including LV stroke volume, stroke index, cardiac output, and cardiac index, were significantly lower (p<0.05 for all) than in the control subjects, whereas LV diastolic Doppler parameters, including mitral valve waves E, A, E/A ratio, and E deceleration time, were similar in both groups. LV ejection fraction at rest as well as the stress-induced increment of the LV ejection fraction were similar in both groups. Our results show that untreated patients with long-term IGF-I deficiency have reduced cardiac dimensions and output but normal LV ejection fraction at rest and LV contractile reserve following stress.
Collapse
Affiliation(s)
- M S Feinberg
- The Heart Institute, Sheba Medical Center, Tel-Hashomer, Israel
| | | | | |
Collapse
|
10
|
Narici M, Ferretti G, Susta D, Faglia G, Sartorio A. Maximum anaerobic performance of childhood-onset GH-deficient adults. Growth Horm IGF Res 1999; 9:228-235. [PMID: 10512688 DOI: 10.1054/ghir.1999.0112] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
To date, physical capacity of adults with GH deficiency (GHD) has been studied in terms of muscle strength, contractile properties and aerobic performance. As a result, scanty data are available regarding the maximum anaerobic performance of these patients with reference to healthy controls. Therefore, the objective of this study was to evaluate maximum anaerobic power of adults with GHD and of age-matched controls by two methods, one testing lactacid power (w.;(c)) through a 15-s-maximal bout on a bicycle ergometer, the other testing alactic power (w.;(j)) through a vertical jump on a force platform. Absolute w.;(c)and w.;(j)values were both found to be 35% lower(P<0.04) in GHD patients than in controls. Similarly, peak pedalling velocity (V(peak)) was 21% lower (P<0.04) in patients. When w.;(c)and w.;(j)were respectively normalized for thigh and lower limb muscle plus bone volumes and V(peak)for muscle length, differences between patients and controls were no longer significant. Furthermore, the rate of power loss during the cycling bout was approximately 35% in both groups. This observation was in line with similar delta (peak minus baseline) lactate capillary blood concentrations, being 6.3 mM/l in patients and 7.5 mM/l in controls (NS). Lactacid capacity, which represents the energy extracted from lactate metabolism, normalized for body mass was similar in the two groups. In conclusion, the maximum anaerobic power that can be developed by short-statured childhood-onset GHD adults is significantly lower in terms of absolute values, but not different from that of controls once appropriately normalized. Therefore, the changes in maximum anaerobic power of GH deficient patients seem to be a consequence of their smaller muscle mass.
Collapse
Affiliation(s)
- M Narici
- Section of Physiology, Istituto di Tecnologie Biomediche Avanzate, Consiglio Nazionale delle Ricerche, Milano, Italy
| | | | | | | | | |
Collapse
|
11
|
Janssen YJ, Doornbos J, Roelfsema F. Changes in muscle volume, strength, and bioenergetics during recombinant human growth hormone (GH) therapy in adults with GH deficiency. J Clin Endocrinol Metab 1999; 84:279-84. [PMID: 9920096 DOI: 10.1210/jcem.84.1.5411] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Adults with GH deficiency (GHD) suffer from muscle weakness, which can be caused by the frequently reported decrease in muscle mass. However, measurements of both muscle strength and mass of muscle tested are scarce in adults with GHD. The aim of the present study was, therefore, to investigate intrinsic muscle strength (strength expressed per muscle volume unit) in adults with GHD at baseline and after 52 weeks of recombinant human GH (rhGH) therapy given in low, more physiological doses. A second objective was to investigate the influence of GH on muscle bioenergetics in the resting muscle. Isometric and isokinetic quadriceps strengths were measured in 28 males with GHD and in healthy controls matched for age and height. Quadriceps mass, determined by magnetic resonance imaging, and muscle bioenergetics, determined by phosphorus nuclear magnetic resonance spectroscopy, were measured in 20 of 28 patients with GHD and in controls matched for age and height. All patients were treated with doses of rhGH ranging from 0.6-1.8 IU/day, given for 52 weeks. Measurements of muscle mass, strength, and bioenergetics were repeated after 52 weeks of treatment with rhGH. The mean GH dose at 52 weeks of rhGH treatment was 1.3 +/- 0.8 IU/day. The mean serum insulin-like growth factor I level at baseline was 9.4 +/- 0.7 nmol/L and significantly increased to 26.4 +/- 1.2 nmol/L after 52 weeks of rhGH treatment. Adults with GHD had significantly reduced quadriceps muscle mass (P = 0.034) and reduced isometric muscle strength (P = 0.002) and tended to have low isokinetic muscle strength (P = 0.06), which all improved after rhGH therapy. Intrinsic muscle strength was not significantly different in adults with GHD compared with that in healthy controls and did not change during rhGH therapy. No bioenergetic abnormalities at baseline or after rhGH therapy were found in males with GHD. In conclusion, quadriceps muscle mass is decreased in adults with GHD and increased with rhGH therapy. These changes in muscle mass account for the changes in muscle strength found in these patients, as no changes in intrinsic muscle strength were found.
Collapse
Affiliation(s)
- Y J Janssen
- Department of Endocrinology, Leiden University Medical Center, The Netherlands
| | | | | |
Collapse
|
12
|
Bell W, Davies JS, Evans WD, Scanlon MF. Strength and its relationship to changes in fat-free mass, total body potassium, total body water and IGF-1 in adults with growth hormone deficiency: effect of treatment with growth hormone. Ann Hum Biol 1999; 26:63-78. [PMID: 9974084 DOI: 10.1080/030144699282985] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
Abstract
The present investigation examined changes in strength in growth hormone deficient (GHD) adults following treatment with recombinant human growth hormone (rhGH), and assessed their relationship to changes in fat-free mass (FFM), total body potassium (TBK), total body water (TBW), the concentration of TBK and TBW per kg FFM, and insulin like growth factor-1 (IGF-1). The investigation was double-blind and placebo-controlled for a period of 6 months; this was followed by a period of open treatment for a further 6 months. Patients were assigned randomly to experimental (E) and control (C) groups. In the first 6 months group E received rhGH and group C placebo; in the second 6 months both groups received rhGH. Serial data were analysed for 23 males (11 group E, 12 group C) and 20 females (10 group E, 10 group C). Body composition was assessed by dual energy X-ray absorptiometry, TBK and TBW. Muscle strength was recorded for arm flexion, leg extension and hand grip. Significant increases in FFM occurred in the first 6 months in group E (2.3 kg males, 1.4 kg females) and in the second 6 months in group C (2.4 kg males, 1.4 kg females). There was a modest increase in absolute strength with time, although only three increments were significant (knee extension in group E males and arm flexion in groups E and C females), all of which occurred during the 6-12 month period. Allometric scaling did not improve the identification of significant increments of strength. The mean concentrations of TBK (males 57.0-58.6, females 51.4-53.9 mmol) and TBW (males 0.65-0.69, females 0.65-0.68 l) per kg FFM, were significantly smaller at all stages of the trial than the reference values, suggesting that treatment had not fully normalized these variables. Likewise, the relationship between most of the increments of regional and total strength, and the corresponding increments of FFM, were generally poor and not significant. It was concluded that the reduced concentrations of TBK and TBW per kg FFM, which may be the effect of an inappropriate dose regime or mode of delivery, may, in part, contribute to the anomaly between increases in strength and FFM.
Collapse
Affiliation(s)
- W Bell
- University of Wales Institute, Cardiff, UK
| | | | | | | |
Collapse
|
13
|
Sartorio A, Narici M, Bottinelli R. Different impairment of muscle strength in adults with childhood-onset and acquired GH deficiency. J Clin Endocrinol Metab 1998; 83:712. [PMID: 9467599 DOI: 10.1210/jcem.83.2.4587-1] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
14
|
Johannsson G, Grimby G, Sunnerhagen KS, Bengtsson BA. Two years of growth hormone (GH) treatment increase isometric and isokinetic muscle strength in GH-deficient adults. J Clin Endocrinol Metab 1997; 82:2877-84. [PMID: 9284713 DOI: 10.1210/jcem.82.9.4204] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
GH deficiency in adults is associated with reduced muscle mass and muscle strength. The objective of this trial was to follow the effect of 2 yr of GH treatment in GH-deficient adults on muscle performance in relation to a reference population. Knee extensor and flexor strengths for isometric and isokinetic concentric muscle strength were measured using a Kin-Com dynamometer. Hand-grip strength was measured in both hands. The fatigue index was calculated as the percent reduction in peak torque at 50 repeated isokinetic knee extensions. Superimposed, single twitch electrical stimulation was performed. The GH-deficient subjects had lower isometric knee extensor, knee flexor, and hand-grip strength than the reference population. Two years of GH treatment increased and normalized the mean isometric knee extensor and flexor strengths. The concentric knee flexor and extensor strength at an angular velocity of pi rad/s increased, as did the concentric knee flexor strength at an angular velocity of pi/3 rad/s. The increase in muscle strength was more marked in younger patients and in patients with lower initial muscle strength than predicted. Quadriceps endurance decreased, whereas the effect of superimposing single twitches on isometric contraction and hand-grip strength was unaffected by the GH treatment. Two years of GH therapy in GH-deficient adults increased and normalized isokinetic and isometric muscle strength studied in proximal muscle groups. Hand-grip strength and the degree of lack of maximal motor unit activation on voluntary isometric knee extensor force did not change. The dynamic local muscle fatigue index decreased.
Collapse
Affiliation(s)
- G Johannsson
- Research Center for Endocrinology and Metabolism, Sahlgrenska University Hospital, Goteborg, Sweden
| | | | | | | |
Collapse
|
15
|
Sartorio A, Narici M, Conti A, Giambona S, Ortolani S, Faglia G. Body composition analysis by dual energy x-ray absorptiometry and anthropometry in adults with childhood-onset growth hormone (GH) deficiency before and after six months of recombinant GH therapy. J Endocrinol Invest 1997; 20:417-23. [PMID: 9309541 DOI: 10.1007/bf03347994] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Measurements of total body fat (BF) and fat free mass (FFM) obtained by anthropometry, using the Durnin and Womersley (DW) equations, and by total body dual energy x-ray absorptiometry (DXA) were compared in 8 adults with childhood-onset GH deficiency (GHD) and in 9 healthy subjects. The sensitivity of these two methods in detecting the changes in body composition produced by six months of GH therapy in patients with GHD was also compared. Anthropometric determination of percent BF was calculated from the sum of biceps, triceps, subscapular and suprailiac skinfolds, using the appropriate DW and Siri equations for body density and percent fat estimation. FFM was calculated by subtracting BF from body mass (BM). BF and FFM were also determined by DXA (QDR 1000/W, Hologic Inc). The data obtained from the GHD patients were compared with those recorded in a control group of healthy males, matched for sex, age and physical activity. Body composition obtained by anthropometry: before GH treatment, significant differences existed between patients and controls in terms of BM (mean +/- SD: 45.8 +/- 10.0 vs 71.7 +/- 6.6 kg), percent BF (21.0 +/- 3.2 vs 17.1 +/- 3.7%) and FFM (36.0 +/- 6.5 vs 59.3 +/- 3.7 kg), while body mass index (BMI, kg/m2) values were similar in the two groups. Six months of GH therapy did not change BM and BMI, but caused a significant reduction of percent BF (from 21.0 +/- 3.2 to 18.6 +/- 4.0%) and a rise of FFM (from 36.0 +/- 6.5 to 38.0 +/- 6.7 kg). After treatment, no significant differences were found between percent BF values of patients and controls. Body composition obtained by DXA: BF (22.0 +/- 3.9%) and FFM (37.2 +/- 8.0 kg) of patients significantly differed from those of controls (16.8 +/- 3.7% and 59.8 +/- 3.7 kg) before treatment; after GH treatment, percent BF values (17.7 +/- 4.9%) of patients were similar to those of controls. Anthropometry vs DXA: high correlation (p < 0.001-0.0001, R2 = 0.784-0.988) was found between the percent BF and FFM determined by anthropometry and by DXA for both patients, before and after treatment, and controls. It is noteworthy that, for both BF and FFM, most values were evenly distributed along the identity line, showing no systematic overestimation or underestimation by anthropometry. The relation between DXA and anthropometry was maintained even after GH treatment. These results indicate that body fat and FFM assessment by anthropometry are comparable to those by DXA. GH-induced changes in body composition in hypopituitary adults are detected with the same level of accuracy by the two techniques. The reliability, practicality and low cost of anthropometry favour its use for the assessment of body composition even in GHD patients.
Collapse
Affiliation(s)
- A Sartorio
- Istituto Auxologico Italiano, IRCCS, Milano, Italy
| | | | | | | | | | | |
Collapse
|
16
|
Sartorio A, Ferrero S, Conti A, Bragato R, Malfatto G, Leonetti G, Faglia G. Adults with childhood-onset growth hormone deficiency: effects of growth hormone treatment on cardiac structure. J Intern Med 1997; 241:515-20. [PMID: 10497628 DOI: 10.1111/j.1365-2796.1997.tb00010.x] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
OBJECTIVES To evaluate the effects of growth hormone deficiency (GHD) and of growth hormone (GH) therapy on cardiac structure in adults with childhood-onset GHD. SETTING Out-patient clinic in the Italian Institute for Auxology, Milan. SUBJECTS Eight adults with childhood-onset GHD and eight healthy controls, matched for sex, age, exercise and body mass index. INTERVENTIONS Recombinant GH (Saizen Serono, Italy), administered in a conventional dose of 0.5 IU kg-1 week-1 for 6 months. MAIN OUTCOME MEASURES Cardiac structure parameters, evaluated by two-dimensional, M-mode and Doppler echocardiograms, and stress test, by means of a modified Bruce protocol with a bicycle ergometer, were determined before and after 6 months GH therapy. RESULTS Before treatment, mean (+/- SE) intraventricular septal thickness (IVST: 7.1 +/- 0.2 mm), LV posterior wall thickness (LVPT: 5.2 +/- 0.1 mm), LV mass (LVM: 94.6 +/- 5.0 g), LV mass index (LVM/body surface area, LVMI: 65.1 +/- 3.0 g m-2) and left ventricular end-diastolic diameter (LVED: 41.4 +/- 0.6 mm) of patients were significantly lower (P < 0.01) than in controls, whilst LV end-systolic diameter (LVES) of patients (25.5 +/- 0.7 mm) was similar to controls (27.5 +/- 0.7). GH treatment significantly (P < 0.01) increased LVPT (6.8 +/- 0.2 mm), LVM (111.6 +/- 4.6 g) and LVMI (80.5 +/- 3.5 g m-2); no significant changes were observed in LVED, LVES and IVST values. The stress test showed a significant improvement of cardiac performance, as demonstrated by the reduction of blood pressure x heart rate product at the same workload (basal: 32,722.5 +/- 897.4 vs. after: 25,574.6 +/- 439.7). CONCLUSIONS GH plays a role in the maintenance of a normal cardiac structure in adulthood. The present study suggests that GH treatment might be able to improve the cardiac structure of patients with childhood-onset GHD.
Collapse
Affiliation(s)
- A Sartorio
- Laboratorio Sperimentale di Ricerche Endocrinologiche, Istituto Auxologico Italiano, IRCCS, Milano, Italy
| | | | | | | | | | | | | |
Collapse
|